Quest Diagnostics Buys ConVerge - Analyst Blog
October 08 2013 - 4:05PM
Zacks
Quest Diagnostics Inc. (DGX), a leading
provider of diagnostic information services, announced its takeover
of ConVerge Diagnostic Services, LLC from Water Street Healthcare
Partners, one of the prime investors in the health care industry.
However, the financial terms of the acquisition are yet to be
disclosed.
The acquisition is part of the five-point strategy announced by the
company in 2012. The strategies intend to strengthen DGX's foothold
in the core diagnostic information services business, drive
operational excellence, restore growth, simplify the organizational
structure and deliver disciplined capital deployment. The company
expects to grow 1%-2% through its strategically aligned
acquisitions.
ConVerge Diagnostic is a regional leader in women's health with
good repute for customer service, medical expertise and innovation.
It provides clinical, cytology and anatomic pathology testing
services to patients, physicians and hospitals in New England.
The addition of ConVerge Diagnostic is expected to synergize
perfectly with the Quest Diagnostic's business portfolio. The
acquisition will extend the range of diagnostic information
services for DGX, facilitating greater accessibility of patients in
the region and enhancing better patient outcomes in the long run.
The transaction paves the way for both the companies to discover
new medical innovations that can spur better patient outcomes.
ConVerge Diagnostic is the fourth laboratory acquisition of
Quest Diagnostics in 2013 and the second in Massachussets, after
the Jan 2013 acquisition of UMass Memorial Medical Center's
clinical and anatomic pathology outreach laboratory businesses in
Worcester, MA.
Following the acquisition, ConVerge Diagnostic will become a
wholly-owned subsidiary of Quest Diagnostics. Its laboratory in
Peabody, MA, and its patient service centers currently functioning
in Massachusetts, New Hampshire and Connecticut will operate as
part of Quest Diagnostic's national laboratory network. Eventually
the ConVerge laboratory will be integrated into the one-of-a kind
laboratory facility being built by Quest Diagnostics in
Marlborough, Mass.
Following the announcement of the five-point strategy, Quest
Diagnostics has been rigorously trying to pursue it for robust
organizational excellence. As a part of its plan to remain focused
on the core diagnostic information services business, DGX has
already divested its non-core assets, selling its OralDNA dental
diagnostics, HemoCue diagnostic products, Ibrutinib royalty rights
and Enterix colorectal-cancer product businesses. The divestments
have generated gross proceeds of $800 million, which in turn, has
propelled enhanced shareholder value.
On the hand, the strategy of delivering an effective capital
deployment is being affected through cautious acquisitions made by
Quest Diagnostics in 2013 including the Tennessee-based toxicology
and clinical laboratory business of Concentra, a Humana business,
and lab-related clinical outreach operations of Dignity Health in
California and Nevada.
Quest expects the ConVerge acquisition to be neutral to adjusted
earnings per share in 2013. It, however, expects the transaction to
be modestly accretive to adjusted earnings in 2014.
DGX currently carries a Zacks Rank #3 (Hold). Other stocks that are
worth a look include LCA-Vision Inc. (LCAV),
LHC Group, Inc. (LHCG), each of them carries a
Zacks Rank #1 (Strong Buy), and AmSurg Corp.
(AMSG), carrying a Zacks Rank #2 (Buy).
AMSURG CORP (AMSG): Free Stock Analysis Report
QUEST DIAGNOSTC (DGX): Free Stock Analysis Report
LCA-VISION INC (LCAV): Free Stock Analysis Report
LHC GROUP LLC (LHCG): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
(MM) (NASDAQ:LCAV)
Historical Stock Chart
From Jun 2024 to Jul 2024
(MM) (NASDAQ:LCAV)
Historical Stock Chart
From Jul 2023 to Jul 2024